Strides Pharma Science Limited has informed about Pronouncement of Order by the Hon ble NCLT, Bengaluru Bench regarding Scheme of Arrangement for Demerger of Demerged Undertaking of Arco Lab Private Limited, a wholly owned subsidiary of Strides Pharma Science Limited.
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Strides Pharma Science's wholly owned subsidiary Arco Lab Private Limited has received NCLT Bengaluru Bench approval for a scheme of arrangement. Under this scheme, Arco Lab's Life Sciences and Digital Innovation businesses (the Demerged Undertaking) will be demerged into Pivot Path Private Limited, another wholly owned subsidiary. The NCLT pronounced its order on May 18, 2026, and the certified copy is expected soon. Upon the scheme becoming effective, Pivot Path will become a direct wholly owned subsidiary of Strides, and Strides will receive equity shares in Pivot Path as per the share entitlement ratio in the scheme. The appointed date for the demerger is April 10, 2025. The company will notify the effective date once the formalities are complete.
This is an internal corporate restructuring that will restructure Strides' subsidiary ownership, creating a new listed entity (Pivot Path) under the Strides group. Shareholders should watch for the official share entitlement ratio and effective date announcement, which will determine how Pivot Path shares are allotted to Strides shareholders.